Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa.
作者信息
Das Kaushik, Pendurthi Usha R, Manco-Johnson Marylyn, Martin Erika J, Brophy Donald F, Rao L Vijaya Mohan
机构信息
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
School of Medicine, University of Colorado, Aurora, Colorado, USA.
出版信息
J Thromb Haemost. 2022 Aug;20(8):1928-1933. doi: 10.1111/jth.15768. Epub 2022 Jun 6.
Abstract
摘要
相似文献
1
Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa.凝血因子VIIa治疗可增加血友病患者循环中的细胞外囊泡：对FVIIa治疗性止血作用的启示。
J Thromb Haemost. 2022 Aug;20(8):1928-1933. doi: 10.1111/jth.15768. Epub 2022 Jun 6.
2
The role of tissue factor and factor VIIa in hemostasis.组织因子和因子VIIa在止血中的作用。
Anesth Analg. 2009 May;108(5):1447-52. doi: 10.1213/ane.0b013e31819bceb1.
3
Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.组织因子和因子VIIa作为止血障碍的治疗靶点。
Annu Rev Med. 2008;59:29-41. doi: 10.1146/annurev.med.59.061606.095605.
4
Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect.因子 VIIa 诱导血管内皮细胞释放细胞外囊泡：其止血作用的潜在机制。
Blood. 2021 Jun 17;137(24):3428-3442. doi: 10.1182/blood.2020008417.
5
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.高剂量凝血因子VIIa（FVIIa）在基于细胞的止血模型中的作用。
Dis Mon. 2003 Jan;49(1):14-21. doi: 10.1053/mda.2003.29504b.
6
Plasma-derived factors VIIa and X mixtures (Byclot) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients.血浆来源的因子 VIIa 和 X 混合物（Byclot）可显著改善获得性血友病 A 患者血浆体外凝血潜能的损伤。
Int J Hematol. 2020 Jun;111(6):779-785. doi: 10.1007/s12185-020-02837-6. Epub 2020 Feb 6.
7
Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.采用旋转血栓弹性描记术对伴有抑制剂的血友病 A 患者围手术期的止血管理进行系统监测。
J Thromb Haemost. 2015 Jul;13(7):1279-84. doi: 10.1111/jth.12987. Epub 2015 May 29.
8
Intraoral hemostasis using a recombinant activated factor VII preparation in a hemophilia a patient with inhibitor.在一名患有抑制物的甲型血友病患者中使用重组活化凝血因子VII制剂进行口腔内止血。
J Oral Maxillofac Surg. 2003 Sep;61(9):1095-7. doi: 10.1016/s0278-2391(03)00324-0.
9
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.重组凝血因子VIIa在血友病患者出血发作控制中的最佳应用。
Drug Des Devel Ther. 2010 Jul 21;4:127-37. doi: 10.2147/dddt.s6628.
10
MicroRNA-10a enrichment in factor VIIa-released endothelial extracellular vesicles: potential mechanisms.miRNA-10a 在因子 VIIa 释放的血管内皮细胞外囊泡中的富集：潜在机制。
J Thromb Haemost. 2024 Feb;22(2):441-454. doi: 10.1016/j.jtha.2023.10.021. Epub 2023 Nov 4.
引用本文的文献
1
MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.肺癌中的微小RNA：它们在肿瘤进展、生物标志物、诊断、预后及治疗相关性中的作用
Discov Oncol. 2025 Mar 11;16(1):293. doi: 10.1007/s12672-025-02054-9.
2
Recombinant factor VIIa: new insights into the mechanism of action through product innovation.重组凝血因子VIIa：通过产品创新对作用机制的新见解。
Res Pract Thromb Haemost. 2024 Dec 31;9(1):102670. doi: 10.1016/j.rpth.2024.102670. eCollection 2025 Jan.
3
The role of extracellular vesicles in the pathogenesis of gynecological cancer.细胞外囊泡在妇科癌症发病机制中的作用。
Front Oncol. 2024 Sep 26;14:1477610. doi: 10.3389/fonc.2024.1477610. eCollection 2024.
4
Coagulation protease-induced extracellular vesicles: their potential effects on coagulation and inflammation.凝血蛋白酶诱导的细胞外囊泡：它们对凝血和炎症的潜在影响。
J Thromb Haemost. 2024 Nov;22(11):2976-2990. doi: 10.1016/j.jtha.2024.07.022. Epub 2024 Aug 8.
5
Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy.凝血蛋白酶驱动的癌症免疫逃逸：癌症免疫治疗的潜在靶点
Cancers (Basel). 2024 Apr 19;16(8):1568. doi: 10.3390/cancers16081568.
6
A potential mechanism for the cytoprotective effects of activated protein C-released endothelial extracellular vesicles.活化蛋白 C 释放的内皮细胞外囊泡的细胞保护作用的潜在机制。
Blood. 2024 Apr 18;143(16):1670-1675. doi: 10.1182/blood.2023023518.
7
MicroRNA-10a enrichment in factor VIIa-released endothelial extracellular vesicles: potential mechanisms.miRNA-10a 在因子 VIIa 释放的血管内皮细胞外囊泡中的富集：潜在机制。
J Thromb Haemost. 2024 Feb;22(2):441-454. doi: 10.1016/j.jtha.2023.10.021. Epub 2023 Nov 4.
8
Factor VIIa releases phosphatidylserine-enriched extracellular vesicles from endothelial cells by activating acid sphingomyelinase.因子 VIIa 通过激活酸性鞘磷脂酶从血管内皮细胞释放富含磷脂酰丝氨酸的细胞外囊泡。
J Thromb Haemost. 2023 Dec;21(12):3414-3431. doi: 10.1016/j.jtha.2023.08.025. Epub 2023 Oct 22.
9
Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.三阴性乳腺癌中的细胞外囊泡：免疫调节、生物标志物及免疫治疗潜力
Cancers (Basel). 2023 Oct 7;15(19):4879. doi: 10.3390/cancers15194879.
10
Beyond Macromolecules: Extracellular Vesicles as Regulators of Inflammatory Diseases.超越大分子：细胞外囊泡作为炎症性疾病的调节因子
Cells. 2023 Jul 29;12(15):1963. doi: 10.3390/cells12151963.
本文引用的文献
1
The impact of storage on extracellular vesicles: A systematic study.储存对细胞外囊泡的影响：一项系统研究。
J Extracell Vesicles. 2022 Feb;11(2):e12162. doi: 10.1002/jev2.12162.
2
Factor VIIa suppresses inflammation and barrier disruption through the release of EEVs and transfer of microRNA 10a.因子 VIIa 通过释放外泌体和转移 microRNA10a 来抑制炎症和屏障破坏。
Blood. 2022 Jan 6;139(1):118-133. doi: 10.1182/blood.2021012358.
3
Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation.为生物医学应用保存细胞外囊泡：分离前后的储存稳定性考虑。
Drug Deliv. 2021 Dec;28(1):1501-1509. doi: 10.1080/10717544.2021.1951896.
4
Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect.因子 VIIa 诱导血管内皮细胞释放细胞外囊泡：其止血作用的潜在机制。
Blood. 2021 Jun 17;137(24):3428-3442. doi: 10.1182/blood.2020008417.
5
The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.《瑞斯托霉素辅因子 VII 在 Glanzmann 血小板无力症患者中的应用》
Thromb Haemost. 2021 Mar;121(3):332-340. doi: 10.1055/s-0040-1718373. Epub 2020 Oct 29.
6
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.治疗剂量的重组 VII 因子在血友病中通过血小板依赖和非依赖机制生成凝血酶。
J Thromb Haemost. 2020 Aug;18(8):1911-1921. doi: 10.1111/jth.14881. Epub 2020 Jun 25.
7
Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.重组人凝血因子VIIa（rFVIIa）在血友病中的作用机制及目前的证据。
Ther Adv Hematol. 2017 Dec;8(12):345-352. doi: 10.1177/2040620717737701. Epub 2017 Nov 3.
8
Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications.治疗应用中外泌体的保存和储存稳定性。
AAPS J. 2017 Nov 27;20(1):1. doi: 10.1208/s12248-017-0160-y.
9
Methodological Guidelines to Study Extracellular Vesicles.研究细胞外囊泡的方法学指南。
Circ Res. 2017 May 12;120(10):1632-1648. doi: 10.1161/CIRCRESAHA.117.309417.
10
Monitoring rFVIII prophylaxis dosing using global haemostasis assays.使用全球止血测定法监测 rFVIII 预防治疗剂量。
Haemophilia. 2013 May;19(3):409-14. doi: 10.1111/hae.12110. Epub 2013 Mar 19.
Zotero 插件